Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib

M Breccia*, R Latagliata, F Stagno, L Luciano, A Gozzini, F Castagnetti, C Fava, F Cavazzini, M Annunziata, A Russo Rossi, P Pregno, E Abruzzese, P Vigneri, G Rege Cambrin, Simona Sica, F Pane, V Santini, G Specchia, G Rosti, G. Alimena

*Autore corrispondente per questo lavoro

Risultato della ricerca: Contributo in rivistaArticolo

47 Citazioni (Scopus)

Abstract

Comorbidities may affect survival and choice of treatment among cancer patients. In fact, comorbidities have been identified as significant determinants of response to therapy in older patients with acute myeloid leukemia, breast cancer, head and neck cancer, and lung cancer. The Charlson comorbidity index and adult comorbidity evaluation-27 are lists of comorbidities with a weight assigned from 1 to 6 for the former and from 0 to 3 for the latter score, derived from relative risk estimates of a proportional hazard regression model using clinical data.
Lingua originaleInglese
pagine (da-a)1457-1461
Numero di pagine5
RivistaHaematologica
Volume96
Numero di pubblicazione10
DOI
Stato di pubblicazionePubblicato - 2011

All Science Journal Classification (ASJC) codes

  • Ematologia

Keywords

  • Aged
  • Antineoplastic Agents
  • BCR-ABL Positive
  • Chronic
  • Female
  • Humans
  • Incidence
  • Leukemia
  • Male
  • Medication Adherence
  • Myelogenous
  • Pleural Effusion
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Retrospective Studies
  • Thiazoles
  • Treatment Outcome

Fingerprint

Entra nei temi di ricerca di 'Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib'. Insieme formano una fingerprint unica.

Cita questo